Krazati (adagrasib) — CareFirst (Caremark)
unresectable, resected gross residual (R2), or metastatic biliary tract cancers including intrahepatic and extrahepatic cholangiocarcinoma and gallbladder cancer
Initial criteria
- Requested medication will be used as a single agent
- Tumor or plasma specimen is positive for KRAS G12C mutation
Reauthorization criteria
- No evidence of unacceptable toxicity or disease progression while on the current regimen
Approval duration
12 months